These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 9205076)
1. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Brüggemann SK; Kisro J; Wagner T Cancer Res; 1997 Jul; 57(13):2676-80. PubMed ID: 9205076 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637 [TBL] [Abstract][Full Text] [Related]
3. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells. Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823 [TBL] [Abstract][Full Text] [Related]
4. Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7. Knouzy B; Dubourg L; Baverel G; Michoudet C J Appl Toxicol; 2010 Apr; 30(3):204-11. PubMed ID: 19774546 [TBL] [Abstract][Full Text] [Related]
5. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity. Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610 [TBL] [Abstract][Full Text] [Related]
6. Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy. Benesic A; Schwerdt G; Freudinger R; Mildenberger S; Groezinger F; Wollny B; Kirchhoff A; Gekle M Kidney Blood Press Res; 2006; 29(5):280-93. PubMed ID: 17035713 [TBL] [Abstract][Full Text] [Related]
8. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987 [TBL] [Abstract][Full Text] [Related]
9. Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. Leclerc E; Hamon J; Bois FY J Appl Toxicol; 2016 Feb; 36(2):330-9. PubMed ID: 26152902 [TBL] [Abstract][Full Text] [Related]
10. Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide. Wiedemann GJ; Siemens HJ; Mentzel M; Biersack A; Wössmann W; Knocks D; Weiss C; Wagner T Cancer Res; 1993 Sep; 53(18):4268-72. PubMed ID: 8364922 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule. Yaseen Z; Michoudet C; Baverel G; Dubourg L Arch Toxicol; 2008 Sep; 82(9):607-14. PubMed ID: 18214444 [TBL] [Abstract][Full Text] [Related]
12. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935 [TBL] [Abstract][Full Text] [Related]
13. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Brüggemann SK; Radike K; Braasch K; Hinrichs J; Kisro J; Hagenah W; Peters SO; Wagner T Cancer Chemother Pharmacol; 2006 Feb; 57(3):349-56. PubMed ID: 16133533 [TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Kurowski V; Wagner T Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587 [TBL] [Abstract][Full Text] [Related]
15. Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer. Mencoboni M; Lerza R; Castello G; Arboscello E; Barsotti BP; Cerruti A; Ballarino P; Botta M; Bogliolo G; Pannacciulli I Anticancer Res; 1997; 17(4A):2795-8. PubMed ID: 9252717 [TBL] [Abstract][Full Text] [Related]
16. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. Springate J; Chan K; Lu H; Davies S; Taub M In Vitro Cell Dev Biol Anim; 1999 Jun; 35(6):314-7. PubMed ID: 10476917 [TBL] [Abstract][Full Text] [Related]
17. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. Aleksa K; Ito S; Koren G J Lab Clin Med; 2004 Mar; 143(3):159-62. PubMed ID: 15007305 [TBL] [Abstract][Full Text] [Related]
18. Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity. MacAllister SL; Martin-Brisac N; Lau V; Yang K; O'Brien PJ Chem Biol Interact; 2013 Feb; 202(1-3):259-66. PubMed ID: 23220588 [TBL] [Abstract][Full Text] [Related]
19. Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. Takahashi K; Sakurai K; Takahashi K; Tanaka H; Fujimoto Y Anticancer Drugs; 2007 Jun; 18(5):543-53. PubMed ID: 17414623 [TBL] [Abstract][Full Text] [Related]
20. Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells. Schwerdt G; Gordjani N; Benesic A; Freudinger R; Wollny B; Kirchhoff A; Gekle M Pediatr Nephrol; 2006 Jan; 21(1):60-7. PubMed ID: 16267686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]